Tularik Exec Moves To XenoPort
This article was originally published in The Pink Sheet Daily
Executive Summary
Former Tularik CFO and General Counsel William Rieflin joined XenoPort as president the week of Sept. 20.
You may also be interested in...
Amgen's $1.3 Bil. Acquisition Of Tularik Would Yield Two Late-Stage Oncologics
Tularik would broaden Amgen's oncology portfolio to small molecules with compounds for hepatocellular carcinoma, and esophageal and gastric cancers. The deal is one-tenth the size of Amgen's last acquisition – the $10 bil. Immunex purchase.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: